View |
|
DR-XY47971 (For Export Use Only)
|
Thiamine mononitrate (Vitamin B1) + Pyridoxine
hydrochloride (Vitamin B6) + Folic Acid (Vitamin B9) +
Cyanocobalamin (Vitamin B12) + Iron
|
Fortifer-FA
|
Each film-coated tablet contains:
Iron, elemental (as Ferrous Fumarate 300 mg) 98.6 mg; Folic Acid 500 mcg; Thiamine Mononitrate (Vitamin B1) 5 mg; Pyridoxine Hydrochloride (Vitamin B6) 5 mg; Cyanocobalamin (Vitamin B12) 15 mcg
|
Film-Coated Tablet
|
Anti-Anemia/Hematinic
|
Amherst Laboratories, Inc.
|
Philippines
|
Initial
|
28 April 2022
|
28 April 2027
|
View |
|
DR-XY47972
|
Gemcitabine
|
Gemibine-2000
|
2g
|
Lyophilized Powder for Injection (IV)
|
-
|
Intas Pharmaceuticals Limited
|
India
|
-
|
28 April 2022
|
28 April 2027
|
View |
|
DR-XY47973
|
Hypromellose
|
Misty
|
3 mg/mL
|
Ophthalmic Solution
|
Surgical Aids (Viscoelastic substances)
|
Millimed BFS Co., Ltd.
|
Thailand
|
Initial
|
28 April 2022
|
28 April 2027
|
View |
|
DR-XY47974
|
Empagliflozin + Metformin Hydrochloride
|
Jardiance Duo
|
12.5mg/850mg
|
Film-Coated Tablet
|
-
|
Boehringer Ingelheim Ellas A.E
|
Greece
|
-
|
29 April 2022
|
29 April 2027
|
View |
|
DR-XY47975
|
Empagliflozin + Metformin Hydrochloride
|
Jardiance Duo
|
12.5mg/500mg
|
Film-Coated Tablet
|
-
|
Boehringer Ingelheim Ellas A.E
|
Greece
|
-
|
29 April 2022
|
29 April 2027
|
View |
|
DR-XY47976
|
Empagliflozin + Metformin Hydrochloride
|
Jardiance Duo
|
5mg/1g
|
Film-Coated Tablet
|
-
|
Boehringer Ingelheim Ellas A.E
|
Greece
|
-
|
29 April 2022
|
29 April 2027
|
View |
|
DR-XY47977
|
Empagliflozin + Metformin Hydrochloride
|
Jardiance Duo
|
5mg/850mg
|
Film-Coated Tablet
|
-
|
Boehringer Ingelheim Ellas A.E
|
Greece
|
-
|
29 April 2022
|
29 April 2027
|
View |
|
DR-XY47978
|
Empagliflozin + Metformin Hydrochloride
|
Jardiance Duo
|
5mg/500mg
|
Film-Coated Tablet
|
-
|
Boehringer Ingelheim Ellas A.E.
|
Greece
|
Initial
|
29 April 2022
|
29 April 2027
|
View |
|
DR-XY47979
|
Teneligliptin (as Hemipentahydrobromide hydrate)
Tenglyn
|
Tenglyn
|
20 mg
|
Film Coated Tablet
|
Antidiabetic Agent (Dipeptidyl peptidase 4 (DPP-4) inhibitors)
|
Cadila Healthcare Limited
|
India
|
Monitored Release (MR)
|
28 April 2022
|
28 April 2027
|
View |
|
DR-XY47980
|
Norepinephrine (as bitartrate)
|
None
|
1 mg/mL (4 mg/4 mL)
|
Concentrate Solution for IV Infusion
|
Adrenergic and dopaminergic agent
|
PT. Novell Pharmaceutical Laboratories
|
Indonesia
|
Initial
|
28 April 2022
|
28 April 2027
|
View |
|
DR-XY47981
|
Salbutamol (as sulfate) + Guaifenesin
|
Izbrid
|
1mg/ 50mg
|
Syrup (Orange Flavor)
|
Bronchodilator/ Expectorant
|
Interphil Laboratories, Inc.
|
Philippines
|
Initial
|
29 April 2022
|
29 April 2027
|
View |
|
DR-XY47982
|
Quetiapine (as fumarate)
|
Q-Mind ER 50
|
50 mg
|
Extended-Release Tablet
|
Antipsychotic
|
Torrent Pharmaceuticals Ltd.
|
India
|
Initial
|
28 April 2022
|
28 April 2027
|
View |
|
DR-XY47983
|
Budesonide
|
Aeronide
|
200mcg per actuation
|
Suspension pressurized Metered Dose Inhaler
|
Glucocorticoid
|
Inpac Pharma Co., Ltd
|
Thailand
|
Initial
|
28 April 2022
|
28 April 2027
|
View |
|
DR-XY47984
|
Fenoterol hydrochloride + ipratropium bromide
|
Aerobidol
|
50 mcg/20 mcg per Actuation
|
Solution Metered Dose Inhaler
|
Selective beta-2-adrenoreceptor
Anticholinergic
|
Inpac Pharma Co., Ltd
|
Thailand
|
Initial (Correction)
|
17 October 2022
|
28 April 2027
|
View |
|
DR-XY47985
|
Metronidazole
|
Siti-zole
|
5 mg/mL (500 mg/ 100 mL)
|
Solution for I.V. Infusion.
|
Antibacterial/ Antiprotozoal (Nitroimidazole Derivative)
|
Shijiazhuang No. 4 Pharmaceutical Co., Ltd
|
China
|
Initial (Correction)
|
14 May 2024
|
28 April 2027
|
View |
DR-XY47986_PI_01.pdf
|
DR-XY47986
|
Olmesartan Medoxomil + Amlodipine (as besilate)
|
Alzor CCB
|
40mg/5mg
|
Film-Coated Tablet
|
Angiotensin II Receptor Blockers (ARBs) and Calcium Channel Blockers
|
Ajanta Pharma Limited
|
India
|
Initial (from Monitored Release status) [Reconstruction]
|
08 February 2023
|
29 April 2027
|
View |
|
DR-XY47987
|
500mg (equivalent to 200mg Ascorbic Acid and 300mg Sodium Ascorbate)
|
Khrizvitcee 500
|
500 mg
|
Chewable Tablet
|
-
|
Reyoung Pharmaceutical Co., Ltd.
|
China
|
-
|
29 April 2022
|
29 April 2027
|
View |
|
DR-XY47988
|
Hidrosmin
|
Venosmil
|
200mg
|
Capsule
|
Capillary Stabilizing Agent (Bioflavonoid)
|
Faes Farma, S.A.
|
Spain
|
Monitored Release (MR)
|
29 April 2022
|
29 April 2027
|
View |
DR-XY47989_PI_01.pdf
|
DR-XY47989
|
Olmesartan Medoxomil + Amlodipine (as besilate)
|
Alzor CCB
|
40mg/10mg
|
Film-Coated Tablet
|
Angiotensin II Receptor Blockers (ARBs) and Calcium Channel Blockers
|
Ajanta Pharma Limited
|
India
|
Initial (from Monitored Release status) [Reconstruction]
|
08 February 2023
|
29 April 2027
|
View |
|
DR-XY47990
|
10% Dextrose In Water
|
None
|
100 g/L (10% w/v)
|
Solution for Intravenous Infusion
|
Parenteral Rehydration Solution
|
Shijiazhuang No.4 Pharmaceutical Co., Ltd.
|
China
|
Initial (Correction)
|
19 January 2023
|
29 April 2027
|